Table 3.

Effects of myo-inositol + melatonin supplementation during ART.

Authors	Species	Myo-inositol + melatonin  in vitro/in vivo	Patients number (tot)	Intervention/control number	Technique	Significant outcomes (p < 0.05)
Pacchiarotti et al. 2016 [73]	Human	Orally administered MI (4 g/day) + FA (400 mcg/day) + M (3 g/day) versus MI (4 g/day) + FA (400 mcg/day) versus FA (400 mcg/day)	526	165/166/195	ICSI IVF-ET	(i) Increased mature oocytes (ii) Increased embryos grade 1 (iii) Reduced days of FSH stimulation (iv) Reduced E2 level before hCG
Unfer et al. 2011 [75]	Human	Orally administered MI (4 g/day) + FA (400 mcg/day) + M (3 g/day) versus previous failed IVF (themselves)	46	46/46	IVF-ET	(i) Increased mature oocytes (MII) (ii) Increased embryos grade 1 (iii) Reduced days and UI of FSH stimulation
Rizzo et al. 2010 [74]	Human	Orally administered MI (4 g/day) + FA (400 mcg/day) + M (3 g/day) versus MI (4 g/day) + FA (400 mcg/day)	65	32/33		(i) Increased mature oocytes (MII) (ii) Increased embryos grade 1-2

MI: myo-inositol; FA: folic acid; M: melatonin; IVF: in vitro fertilization; ET: embryo transfer; ICSI: intracytoplasmic sperm injection; FSH: follicle stimulating hormone; hCG: human chorionic gonadotropin; UI: uterine insemination.